You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昂利康(002940.SZ):浙江白雲山昂利康製藥完成吸收合併
格隆匯 12-25 17:23

格隆匯12月25日丨昂利康(002940.SZ)公佈,公司分別於2019年9月25日和2019年10月17日召開了第二屆董事會第十二次會議和2019年第二次臨時股東大會,審議通過了《關於與廣州白雲山化學藥科技有限公司開展合作備忘錄項下浙江白雲山昂利康製藥有限公司與浙江廣康醫藥有限公司吸收合併事宜的議案》,同意由公司全資子公司浙江白雲山昂利康製藥有限公司(以下簡稱“白雲山昂利康”)吸收合併本公司參股公司浙江廣康醫藥有限公司,吸收合併後,白雲山昂利康繼續存在,廣康公司依法註銷,廣康公司的全部資產、債權債務和業務由吸收合併後的白雲山昂利康依法承繼。

2019年12月25日,公司收到白雲山昂利康的通知,知曉廣康公司註銷登記已被嵊州市市場監督管理局核准。同日,白雲山昂利康完成了吸收合併的工商變更登記手續,並取得了嵊州市市場監督管理局頒發的《營業執照》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account